Dr. Pettit is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Education & Training
University of Chicago Medical CenterFellowship, Clinical Pharmacology, 2014 - 2017- University of ChicagoFellowship, Hematology and Medical Oncology, 2013 - 2016
- University of ChicagoResidency, Internal Medicine, 2010 - 2013
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2010
Certifications & Licensure
MI State Medical License 2017 - 2027
IL State Medical License 2010 - 2017- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsZiftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos
The Lancet. Oncology. 2024-10-01 - Exploring Adolescent and Young Adult Cancer Survivors' Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured Interviews.Robert Knoerl, Katherine Grandinetti, Liat Smener, Emily Doll, Leslie A Fecher
Journal of Adolescent and Young Adult Oncology. 2024-08-01 - 1 citationsTreatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.Anand A Patel, James J Yoon, Hannah Johnston, Marta B Davidson, Rory M Shallis
Blood Advances. 2024-07-09
Abstracts/Posters
- Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with MyelofibrosisKristen Pettit, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AMLKristen Pettit, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory PathwaysKristen Pettit, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Imago BioSciences Preliminary Data from Ongoing Phase 2 Study of IMG-7289 for the Treatment of Myelofibrosis to Be Presented at the 61st American Society of Hematology Annual Meeting & ExpositionOctober 25th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
